Navigation Links
UCLA cancer scientists identify liposarcoma tumors that respond to chemotherapy
Date:12/10/2012

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

Now, using a strategy that tracks cancer cells' consumption of nucleosides, a team of researchers at UCLA's Jonsson Comprehensive Center has identified a group of liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC. Furthermore, they have found that these tumors are sensitive to chemotherapy.

The team's findings are published online in the journal Cancer Discovery and will appear in an upcoming print edition.

Led by Jonsson Cancer Center researcher Heather Christofk, an assistant professor of molecular and medical pharmacology at UCLA, the scientists employed a metabolomic strategy that detected nucleoside salvage activity in liposarcoma cells taken from patient samples, cells grown in the laboratory and cells grown in mouse models. The nucleoside activity was visible using PET with the UCLA-developed FAC probe (FAC PET), which measures the activity of the DNA salvage pathway, a fundamental cell biochemical pathway that acts as a sort of recycling mechanism to help with DNA replication and repair.

FAC was created by slightly altering the molecular structure of the standard chemotherapy drug gemcitabine, and in the current study, the UCLA research team discovered that the liposarcoma cells with high nucleoside salvage activity were sensitive to gemcitabine chemotherapy.

In clinical practice, this strategy might be used to identify liposarcoma patients, at the time of diagnosis, who would respond well to gemcitabine chemotherapy, saving time on other treatments and possibly extending the lives of this sub-group of patients.

"It was a satisfying study because it has translational potential for liposarcoma patients now and this is a deadly disease," Christofk said. "Our metabolomic strategy is also generalizable to treatment strategies for other cancers, and that is something we hope to do."

The study was a collaboration between basic scientists and clinicians, following the translational paradigm of bench-to-bedside discoveries.

"This was an outstanding transdisciplinary project between a diverse group of physician scientists and basic scientists that translates molecular oncology from the laboratory to the clinic in a rapid and clinically relevant manner," said Dr. Fritz Eilber, an associate professor of surgery and of molecular and medical pharmacology at UCLA and an investigator on the study. "The findings from this work can be used to directly impact the care of patients with this morbid and lethal malignancy."


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. The Project for Natural Health Choices Inc. Issues an Advisory for Men to Consume Flavonoids in their Diet to Protect Against Prostate Cancer
2. To fight incurable metastatic breast cancer, resistance must be broken
3. Caffeinated coffee may reduce the risk of oral cancers
4. Abnormal DNA maintenance related to cancer
5. Targeted Prostate Cancer Biopsies Might Improve Care: Study
6. Internet use can reduce fatalistic view of cancer
7. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
8. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
9. Researchers develop novel 3-D culture system for inflammatory breast cancer
10. VABC Responds to Study on Use of Cholesterol Lowering Drug Statins on Cancer Patients
11. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/7/2020)... ... April 07, 2020 , ... Black Jaguar-White Tiger Foundation, the global non-profit is ... Black Jaguar-White Tiger Hemp consists of a chewable tablet and tincture available in a ... foundation has launched. , “It is my great Honor, to finally introduce to you, ...
(Date:4/5/2020)... ... April 04, 2020 , ... MyAdvisor, a ... uniting with the Yellow Ribbon Fund (YRF) to offer mental health and care ... continuing an ongoing partnership to launch a new initiative throughout the global COVID-19 ...
(Date:4/2/2020)... Va. (PRWEB) , ... April 02, 2020 , ... ... Decision Support Software, An FDAnews Webinar, Tuesday April 7, 2020, 1:30-3:00 p.m. EDT, ... to include FDA regulation of AI used to guide clinical management of the ...
(Date:4/2/2020)... ... April 02, 2020 , ... ... their mother’s womb are encouraging their parents, grandparents, and guardians, to file a ... to $6 billion in funds will be made available by Purdue as part ...
(Date:4/1/2020)... , ... April 01, 2020 , ... ... (PPE) to stay safe while treating Coronavirus-infected patients. , Staffers are in particular ... can transmit coronavirus. Earlier this week, The Wall Street Journal reported that New ...
Breaking Medicine News(10 mins):
(Date:4/5/2020)... ... April 04, 2020 , ... Care Oncology, ... undergoing treatment. The company notes that new patient inquiries rose sharply by 35% ... , "Cancer patients feel safer with our telemedicine delivery," says Jason Butcher, Director ...
(Date:4/2/2020)... ... ... Planning an Audit Response:, How to Handle MDSAP Findings, An FDAnews Management ... spotted by a notified body during an audit does happen. What is the best ... pressure with only 15 days to craft a response to the auditing body. , ...
(Date:4/2/2020)... ... 2020 , ... Caitlin Richardson, a University of Washington MEDEX ... Semester Scholarship. , The $1,000 scholarship, awarded biannually to U.S. students who ... helping the students pay tuition and other college-related expenses. , Rhonda Abbe, Director ...
Breaking Medicine Technology: